Oligodendrocyte myelin glycoprotein (OMgp) in rat hippocampus is depleted by chronic ethanol consumption.
The hippocampal formation has been shown to be particularly vulnerable to the neurotoxic effects of chronic ethanol consumption. It was hypothesized that this damage was due to the disruption of the expression of neurotrophic factors and certain other proteins within the hippocampus. By using real-time reverse transcription-polymerase chain reaction (RT-PCR) techniques, this study aimed to determine whether chronic ethanol consumption could alter the mRNA expression level of brain-derived neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF), and oligodendrocyte myelin glycoprotein (OMgp) in the hippocampus. Wistar male rats received an unrestricted access to a liquid diet containing 5% (v/v) ethanol as the sole source of fluid from 10 to 29 weeks of age. Control rats had unlimited access to a liquid diet containing an isocaloric amount of sucrose. We found that chronic ethanol consumption did not cause significant changes in the levels of mRNA for BDNF and GDNF. However, OMgp mRNA showed a significant deficit in ethanol-treated animals. It is suggested that this deficit may be related to the demyelination that is commonly observed in human alcoholics and that this may contribute to the functional and cognitive deficits.
Okamoto
Hanayo
H
Department of Neuropsychiatry, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kagawa 761-0793, Japan.
Miki
Takanori
T
Lee
Kyoung-Youl
KY
Yokoyama
Toshifumi
T
Kuma
Hiromi
H
Wang
Zhi-Yu
ZY
Gu
He
H
Li
Hong-Peng
HP
Matsumoto
Yoshiki
Y
Irawan
Satriotomo
S
Bedi
Kuldip S
KS
Nakamura
Yu
Y
Takeuchi
Yoshiki
Y
D020268:Alcohol-Induced Disorders, Nervous System / Q000139:chemically induced / Q000378:metabolism* / Q000503:physiopathology; D000818:Animals; D001284:Atrophy / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology; D019208:Brain-Derived Neurotrophic Factor / Q000235:genetics; D002492:Central Nervous System Depressants / Q000494:pharmacology; D002908:Chronic Disease; D003711:Demyelinating Diseases / Q000139:chemically induced* / Q000378:metabolism / Q000503:physiopathology; D004195:Disease Models, Animal; D015536:Down-Regulation / Q000187:drug effects / Q000502:physiology; D000431:Ethanol / Q000494:pharmacology*; D058851:GPI-Linked Proteins; D051100:Glial Cell Line-Derived Neurotrophic Factor / Q000235:genetics; D006624:Hippocampus / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008297:Male; D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein / Q000235:genetics*; D063308:Myelin-Oligodendrocyte Glycoprotein; D009413:Nerve Fibers, Myelinated / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D009929:Organ Size / Q000187:drug effects / Q000502:physiology; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar
D019208:Brain-Derived Neurotrophic Factor; D002492:Central Nervous System Depressants; D058851:GPI-Linked Proteins; D051100:Glial Cell Line-Derived Neurotrophic Factor; C571326:MOG protein, human; C571328:Mog protein, rat; D009185:Myelin Proteins; D018992:Myelin-Associated Glycoprotein; D063308:Myelin-Oligodendrocyte Glycoprotein; C560528:OMG protein, human; C560532:Omg protein, rat; D012333:RNA, Messenger; D000431:Ethanol